Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Trinity Biotech (TRIB) Current Assets (2016 - 2025)

Historic Current Assets for Trinity Biotech (TRIB) over the last 17 years, with Q2 2025 value amounting to $33.0 million.

  • Trinity Biotech's Current Assets fell 2823.81% to $33.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $33.0 million, marking a year-over-year decrease of 2823.81%. This contributed to the annual value of $41.1 million for FY2024, which is 533.54% up from last year.
  • Latest data reveals that Trinity Biotech reported Current Assets of $33.0 million as of Q2 2025, which was down 2823.81% from $41.1 million recorded in Q4 2024.
  • Over the past 5 years, Trinity Biotech's Current Assets peaked at $87.6 million during Q1 2021, and registered a low of $33.0 million during Q2 2025.
  • Its 5-year average for Current Assets is $55.2 million, with a median of $49.8 million in 2022.
  • In the last 5 years, Trinity Biotech's Current Assets soared by 2985.37% in 2021 and then tumbled by 3631.19% in 2022.
  • Over the past 5 years, Trinity Biotech's Current Assets (Quarter) stood at $72.7 million in 2021, then tumbled by 35.8% to $46.7 million in 2022, then decreased by 16.34% to $39.0 million in 2023, then grew by 5.34% to $41.1 million in 2024, then fell by 19.76% to $33.0 million in 2025.
  • Its Current Assets stands at $33.0 million for Q2 2025, versus $41.1 million for Q4 2024 and $46.1 million for Q3 2024.